Global Blood Therapeutics

Global Blood Therapeutics. Global Blood Therapeutics was a biopharmaceutical company dedicated to the discovery, development, and delivery of transformative treatments for underserved patient communities, particularly those suffering from sickle cell disease. Founded by a team of renowned scientists, the company rapidly advanced from its inception to bring a first-in-class therapy to market. Its pioneering work focused on addressing the root causes of hemoglobinopathies through innovative small molecule approaches, garnering significant attention within the biotechnology sector and from regulatory bodies like the U.S. Food and Drug Administration.

History

The company was incorporated in 2011 by scientists Matthew M. H. Teng, K. Christopher Garcia, and Jack Taunton, with foundational research stemming from the University of California, San Francisco and Stanford University. Early financing was secured from prominent venture capital firms including Third Rock Ventures, which led the Series A round. In 2012, the company entered a strategic collaboration with Pfizer aimed at discovering novel therapies for sickle cell disease. A significant milestone was reached in 2019 when the U.S. Food and Drug Administration granted accelerated approval for its lead drug, Oxbryta. The company's trajectory culminated in its 2022 acquisition by Pfizer for approximately $5.4 billion, a deal that highlighted the strategic value of its specialized pipeline.

Products and pipeline

The company's flagship product was Oxbryta (voxelotor), an oral, once-daily therapy approved for the treatment of sickle cell disease in patients aged four and older. Oxbryta works as a hemoglobin S polymerization inhibitor, directly targeting the pathological process of sickling. Beyond this commercial asset, the pipeline included GBT601, a next-generation hemoglobin S polymerization inhibitor with improved pharmacokinetic properties. Another key investigational candidate was inclacumab, a P-selectin inhibitor licensed from Roche intended to reduce the frequency of vaso-occlusive crises. The company also engaged in early research exploring potential treatments for other hemoglobinopathies such as beta thalassemia.

Clinical trials and research

The development of Oxbryta was supported by the pivotal Phase III HOPE Trial (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization), results of which were published in the New England Journal of Medicine. This multinational study demonstrated significant increases in hemoglobin levels and reductions in markers of hemolysis. Subsequent studies, including the open-label HOPE-KIDS 2 Trial, supported its approval in the pediatric population. Research on inclacumab advanced through a Phase II study, with data presented at major conferences like the American Society of Hematology annual meeting. The company maintained active Investigational New Drug applications with the U.S. Food and Drug Administration for its entire portfolio.

Corporate affairs

The company was headquartered in South San Francisco, California, within the heart of the San Francisco Bay Area biotechnology cluster. Ted W. Love served as President and Chief Executive Officer, guiding the firm through its initial public offering on the NASDAQ in 2015 and its eventual sale. Key corporate partners over its history included Pfizer, Roche, and the Sickle Cell Disease Association of America. To ensure patient access, the company established GBT Source, a comprehensive support services program. Its corporate governance included a board of directors with experience from leading institutions like Genentech and The Johns Hopkins Hospital.

Impact and recognition

The introduction of Oxbryta represented a paradigm shift in the treatment of sickle cell disease, offering the first therapy that directly inhibits the sickling of red blood cells. This innovation earned the company the 2021 Prix Galien USA Award for "Best Biotechnology Product." Its work significantly raised the profile of sickle cell disease within the pharmaceutical industry, encouraging further investment and research into this historically neglected area. The company was also recognized for its commitment to diversity in clinical trials and its engagement with advocacy groups like the American Society of Hematology and the National Institutes of Health. The acquisition by Pfizer was widely seen as validation of its scientific approach and its potential to deliver meaningful therapies for hematologic diseases.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies established in 2011 Category:Companies based in San Mateo County, California